Discordance between methodologies used to assess the mutational status of other oncogenes and tumor suppressor genes has been noted previously, including HER2 amplification and overexpression in breast cancer [50], TP53 mutations in ovarian cancer [51], BRAF V600E mutation status in colorectal cancer [52], and aberrant cytoplasmic localization of nucleophosmin in acute myeloid leukemia [53]. The gene discussed is BRAF; the disease is ovarian cancer.